Toggle Main Menu Toggle Search

Open Access padlockePrints

Disordered Bile Acid Metabolism in Alcohol-Related Hepatitis

Lookup NU author(s): Dr Steven MassonORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2026 The Author(s). Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.Background: Alcohol-related hepatitis (AH) is characterised by acute cholestasis and liver dysfunction in patients consuming alcohol. Aims: To define the bile acid (BA) profile in AH compared to decompensated alcohol-related cirrhosis (DC) and healthy controls (HC). Methods: Serum and faecal BAs were measured by UHPLC–MS; FGF19 by ELISA; RNA-sequencing data obtained from liver biopsies; serum cytokines and growth factors quantified by multiplex immunoassay. Hepatocyte growth factor (HGF) was applied to primary human hepatocytes (PHH) and BA transporter expression was assessed by RT-qPCR. Results: In two cohorts (Cohort 1: 164 AH, 63 DC, 36 HC; Cohort 2: 94 AH, 175 DC, 72 HC), total serum BAs were highest in AH (median concentration 186.0 μM vs. 64.5 DC vs. 5.0 HC), driven by elevated conjugated primary BAs (182.0 μM vs. 54.0 vs. 2.2). Unconjugated primary BAs were highest in DC. Serum BAs distinguished AH from DC (Cohort 1 AUROC 0.964; Cohort 2 0.922; p < 0.001). Faecal BAs were reduced in AH (0.47 mg/g vs. 1.11 DC vs. 2.64 HC); serum FGF19 elevated (5835 pg/mL AH vs. 865 jaundiced DC [bilirubin > 80 μmol/L]). Serum conjugated BAs correlated negatively with NTCP expression (n = 25, Spearman's rho −0.432, p = 0.031). CYP7A1 was below the limit of detection. HGF was elevated in AH (7899 pg/mL vs. 2607 DC, p < 0.001). HGF treatment reduced PHH BSEP expression. Conclusion: Serum conjugated primary BAs accumulate in AH. Elevated HGF may detrimentally affect the hepatoprotective adaptive reduction in NTCP/increase in BSEP seen in cholestasis, contributing to the AH BA profile.


Publication metadata

Author(s): Tyson LD, Atkinson S, Mullish BH, Pechlivanis A, Allison M, Austin A, Chappell K, Forbes SJ, Forrest EH, Kilpatrick AM, Liu T, Martinez-Gili L, Masson S, McPhail MJW, Nunes J, Richardson P, Rodrigo-Torres D, Ryder SD, Wright M, Patel VC, Vergis N, Holmes E, Thursz MR

Publication type: Article

Publication status: Published

Journal: Alimentary Pharmacology and Therapeutics

Year: 2026

Pages: epub ahead of print

Online publication date: 23/03/2026

Acceptance date: 04/03/2026

Date deposited: 14/04/2026

ISSN (print): 0269-2813

ISSN (electronic): 1365-2036

Publisher: John Wiley and Sons Inc

URL: https://doi.org/10.1111/apt.70616

DOI: 10.1111/apt.70616

Data Access Statement: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
08 14 44
CL-2019-21-002
Health Technology Assessment Programme
Imperial College Healthcare NHS Trust
Imperial College London
MR/Z504002/1
MC_PC_12025
Medical Research Council
National Institute for Health and Care Research
MR/R014019/1
NIHR Imperial Biomedical Research Centre

Share